GenSight Biologics Announces Publication of a Study of the impact of LHON disease on the lives of Patients and Relatives in Journal of Neuro-Ophthalmology

GenSight Biologics Granted Six-Month Extension in LUMEVOQ® European Regulatory Review

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing Timeline

GenSight Biologics to Present REFLECT Phase III Data with LUMEVOQ® at the NANOS 2022 Meeting

GenSight Biologics reports clinically meaningful vision improvement is maintained 4 years after one-time treatment with LUMEVOQ® gene therapy

GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US

GenSight Biologics Announces Extension of Day 120 Clock Stop of LUMEVOQ® EMA Regulatory Filing; MAA Review to Resume in April 2022